Market Overview:
- The global mRNA vaccines and therapeutics market size reached US$ 57.7 Billion in 2023.
- The market is expected to reach US$ 72.7 Billion by 2032, exhibiting a growth rate (CAGR) of 2.53% during 2024-2032.
- Europe’s leads the market, accounting for the largest mRNA vaccines and therapeutics market share.
- The escalating prevalence of complex diseases like cancer and HIV is fueling the rapid expansion of the mRNA vaccines and therapeutics market, driven by their unique therapeutic protein production capabilities.
- Synthetic biology and bioinformatics breakthroughs are pivotal, enabling precise mRNA design and delivery, and broadening applications from infectious diseases to genetic disorders and cancers.
- mRNA therapies represent a potential healthcare revolution, offering molecular-level disease targeting and personalized treatment options, attracting significant market interest.
- Enhanced genomic understanding and gene editing advancements are accelerating mRNA technology, leading to more effective and diverse therapeutic interventions.
- The ability of mRNA to instruct the body to produce its own therapeutic proteins is driving market growth, as healthcare providers and patients recognize its potential to address a wide range of diseases.
This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.
Grab a sample PDF of this report: https://www.imarcgroup.com/mrna-vaccines-therapeutics-market/requestsample
Our report includes:
- Market Dynamics
- Market Trends And Market Outlook
- Competitive Analysis
- Industry Segmentation
- Strategic Recommendations
Factors Affecting the Growth of the mRNA Vaccines and Therapeutics Industry:
- Advancements in mRNA Technology:
The rapid growth of mRNA technology is a key driver in the mRNA vaccines and therapeutics market. Advances in synthetic biology, nanoparticle delivery, and mRNA stability have made these treatments both safer and more effective. This progress helps create targeted vaccines and therapies for many diseases, such as infections and cancer. For instance, lipid nanoparticle delivery systems shield mRNA from degradation. This helps it enter cells better. Also, improved mRNA synthesis lowers the chance of unwanted immune responses. The flexible mRNA technology can quickly adapt to new pathogens or variants. This ability is vital for fighting diseases like COVID-19.
- Increased Focus on Pandemic Preparedness and Emerging Infectious Diseases:
The COVID-19 pandemic highlighted the need for quick vaccine development and global readiness. Vaccines like Moderna and Pfizer-BioNTech, which use mRNA technology, show how fast we can tackle new diseases. This has prompted governments, medical groups, and private companies to invest heavily in mRNA vaccine platforms. They see these platforms as key to preparing for future pandemics. A major advantage of mRNA technology is its speed in development and production. This allows for quick vaccine creation, testing, and manufacturing. It offers a big advantage over slower, traditional methods. The mRNA platform can easily adapt to new virus strains and mutations. This means vaccines can be updated quickly. The speed and flexibility of mRNA treatments make them attractive for future pandemics. This feature also drives ongoing market growth.
- Growing Investment and Partnerships in Biopharmaceutical Research and Development:
The mRNA vaccines and treatments market is being propelled by an increase in funding from both the public and private sectors. Venture capital, pharmaceutical companies, and government funding have been pouring into mRNA research and development, given the success and potential of this technology. For instance, the substantial funding provided by governments worldwide during the COVID-19 pandemic expedited the development and rollout of mRNA vaccines. Additionally, biopharmaceutical companies are forming strategic partnerships and collaborations to speed up the development of mRNA-based therapeutics. By working together, they can share knowledge, technology, and resources, which is essential for overcoming the scientific and regulatory hurdles in creating new mRNA products. Moreover, investments are concentrated on infectious disease vaccines, and they are also branching out into other areas, such as oncology, where mRNA is being explored as a potential platform for cancer vaccines and personalized cancer treatments.
Leading Companies Operating in the Global mRNA Vaccines and Therapeutics Industry:
- Arcturus Therapeutics Inc.
- BioNTech SE
- CureVac AG
- eTheRNA immunotherapies NV
- ethris GmbH
- GlaxoSmithKline PLC
- Moderna Therapeutics Inc.
- Translate Bio Inc.
- Argos Therapeutics, Inc.
- Sangamo Therapeutics Inc.
- Pfizer Inc.
mRNA Vaccines and Therapeutics Market Report Segmentation:
By Vaccine Type:
- Self-amplifying mRNA-Based Vaccines
- Conventional Non-Amplifying mRNA-Based Vaccines
Conventional non-amplifying mRNA-based vaccines dominate the market due to their proven efficacy, safety profile, and rapid scalability, as demonstrated during the COVID-19 pandemic.
By Treatment Type:
- Bioengineered Vaccine
- Gene Therapy
- Gene Transcription
- Cell Therapy
- Monoclonal Antibody
- Others
Bioengineered vaccine represents the largest segment as they offer precise targeting, rapid development, and enhanced efficacy, making them highly effective against a wide range of infectious diseases.
By Vaccine Manufacturing:
- In-House
- Out-Sourced
In-house manufacturing holds the maximum number of shares as it allows companies to maintain control over the production process, ensure quality, scale rapidly, and protect proprietary technologies, all of which are critical for the timely and efficient production of vaccines.
By Application:
- Cancer
- Infectious Disease
- Gene Editing
- Protein Replacement
Infectious disease dominates the market as mRNA vaccines have demonstrated rapid development, high efficacy, and adaptability in responding to emerging pathogens, such as during the COVID-19 pandemic, driving significant demand and investment in this area.
By End-User:
- Hospitals and Clinics
- Research Organizations
- Others
Hospitals and clinics represent the largest segment as they are the primary points of care where mRNA vaccines and therapeutics are administered, monitored, and managed, ensuring accessibility and patient compliance
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Europe’s dominance in the mRNA vaccines and therapeutics market is attributed to its strong biopharmaceutical infrastructure, substantial public and private investment in research and development, and a supportive regulatory environment for innovative medical technologies.
Research Methodology:
The report employs a comprehensive research methodology, combining primary and secondary data sources to validate findings. It includes market assessments, surveys, expert opinions, and data triangulation techniques to ensure accuracy and reliability.
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145